<DOC>
	<DOCNO>NCT00825929</DOCNO>
	<brief_summary>Due potential pregnancy-induced change pharmacokinetics medication , one assume currently license dos medication test protocol lead adequate exposure HIV-infected pregnant woman . For agent study limit pharmacokinetic data pregnancy available . As change pharmacokinetics pregnancy prominent third trimester pharmacokinetic curve record third trimester attain steady state .</brief_summary>
	<brief_title>Pharmacokinetics Antiretroviral Agents HIV-infected Pregnant Women .</brief_title>
	<detailed_description>The following agent study : Etravirine , Intelence , TMC125 ; Emtricitabine , Emtriva FTC ; Tenofovir , Viread , TDF ; Atazanavir , Reyataz ; Fosamprenavir , Telzir , FPV ; Darunavir , Prezista , TMC114 ; Tipranavir , Aptivus , TPV ; Indinavir , Crixivan ; abacavir ; raltegravir , Isentress ; Enfuvirtide , Fuzeon ; Maraviroc , Celsentri ; dolutegravir ; elvitegravir/cobicistat ; rilpvirine</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>HIVinfected document positive HIV antibody test confirm Western Blot . Subject least 18 year age screening . Subject able willing sign Informed Consent Form prior screen evaluation . Treated HAART regimen contain least one agent mention Appendix 1 protocol ; agent take least 2 week day first PK curve evaluation . Duration pregnancy longer 33 week day screen Subject able adhere food intake recommendation . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . Inability understand nature extent study procedure require . Presence grade III/IV anemia ( i.e . Hb &lt; 4.6 mmol/L &lt; 7.4 g/dL )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>pregnancy</keyword>
	<keyword>antiretrovirals</keyword>
	<keyword>neonate</keyword>
	<keyword>HIV</keyword>
	<keyword>treatment experience</keyword>
</DOC>